In urothelial carcinoma, FGFR3 mutations are most prevalent, with an overall frequency of approximately 15–20%; detection rates reach 40–50% in non-muscle-invasive bladder cancer but decline to 10–15% in muscle-invasive or metastatic disease [56,57,58]. The gene discussed is FGFR3; the disease is urothelial carcinoma.